What is claimed is:

1. A compound of the Formula Ia:



Ia

or a pharmaceutically acceptable salt or solvate thereof

wherein,

L- is a Ligand unit;

-A- is a Stretcher unit;

a is 0 or 1;

each -W- is independently an Amino Acid unit;

-Y- is a Spacer unit;

w is an integer ranging from 0 to 12;

y is 0, 1 or 2;

p ranges from 1 to about 20; and

-D is a Drug unit of the formula



wherein, independently at each location:

R^2 is selected from -H and -C_1-C_8 alkyl;

R^3 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

R^4 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle) wherein R^5 is selected from -H and -methyl; or R^4 and R^5 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

wherein,

L- is a Ligand unit;

-A- is a Stretcher unit;

a is 0 or 1;

each -W- is independently an Amino Acid unit;

-Y- is a Spacer unit;

w is an integer ranging from 0 to 12;

y is 0, 1 or 2;

p ranges from 1 to about 20; and

-D is a Drug unit of the formula

wherein, independently at each location:



R^1 is selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle; and R^2 is selected from -H and -C_1-C_8 alkyl; or R^1 and R^2 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached;

R^3 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

R^4 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle) wherein R^5 is selected from -H and -methyl; or R^4 and R^5 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

R^6 is selected from -H and -C_1-C_8 alkyl;

R^7 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

each R^8 is independently selected from -H, -OH, -C_1-C_8 alkyl, -C_3-C_8 carbocycle and -O-(C_1-C_8 alkyl);

R^9 is selected from -H and -C_1-C_8 alkyl;

when R^1 is -C_1-C_8 alkyl, -C_3-C_8 carbocycle, or R^1 and R^2 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached, R^{10} is selected from





, and

, and

when R^1 is -H, R^{10} is selected from:




, and

;

X is -O-, -S-, -NH- or -N(R^{14})-, where X is bonded to Y when y is 1 or 2, or X is bonded to W when y is 0;

Z is -O-, -S-, -NH- or -N(R^{14})-;

R^{11} is selected from -H, -OH, $-NH_2$, $-NHR^{14}$, $-N(R^{14})_2$, $-C_1$-C_8 alkyl, $-C_3$-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, $-C_1$-C_8 alkyl-aryl, $-C_1$-C_8 alkyl-(C_3-C_8 carbocycle), $-C_3$-C_8 heterocycle and $-C_1$-C_8 alkyl-(C_3-C_8 heterocycle); or R^{11} is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;

each R^{12} is independently selected from -aryl and $-C_3$-C_8 heterocycle;

R^{13} is selected from -H, -OH, $-NH_2$, $-NHR^{14}$, $-N(R^{14})_2$, $-C_1$-C_8 alkyl, $-C_3$-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, $-C_1$-C_8 alkyl-aryl, $-C_1$-C_8 alkyl-(C_3-C_8 carbocycle), C_3-C_8 heterocycle and $-C_1$-C_8 alkyl-(C_3-C_8 heterocycle);

each R^{14} is independently independently -H or $-C_1$-C_8 alkyl; and

R^{15} is selected from -arylene-, $-C_3$-C_8 carbocyclo and $-C_3$-C_8 heterocyclo-.

4. The compound of claim 3 wherein w is an integer ranging from 2 to 12.

5. A compound of the formula Ic:



Ic

or a pharmaceutically acceptable salt or solvate thereof

wherein,

L- is a Ligand unit;

-A- is a Stretcher unit;

a is 0 or 1;

each -W- is independently an Amino Acid unit;

w is an integer ranging from 0 to 12;

each n is independently 0 or 1;

p ranges from 1 to about 20; and

each -D is independently:

(a) a Drug unit of the formula:



wherein, independently at each location:

R^1 is selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle; and R^2 is selected from -H and -C_1-C_8 alkyl; or R^1 and R^2 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached;

R^3 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

R^4 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle) wherein R^5 is selected from -H and -methyl; or R^4 and R^5 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

R^6 is selected from -H and -C_1-C_8 alkyl;

R^7 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

each R^8 is independently selected from -H, -OH, -C_1-C_8 alkyl, -C_3-C_8 carbocycle and -O-(C_1-C_8 alkyl);

R^9 is selected from -H and -C_1-C_8 alkyl;

when R^1 is -C_1-C_8 alkyl, -C_3-C_8 carbocycle, or R^1 and R^2 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached, R^{10} is selected from





when R^1 is -H, R^{10} is selected from:





X is -O-, -S-, -NH- or -N(R^{14})-, where X is bonded to -C(O)- when y is 1 or 2, or X is bonded to -CH_2- when n is 0;

Z is -O-, -S-, -NH- or -N(R^{14})-;

R^{11} is selected from -H, -OH, -NH_2, -NHR^{14}, -N(R^{14})$_2$, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle); or R^{11} is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;

each R^{12} is independently selected from -aryl and -C_3-C_8 heterocycle;

R^{13} is selected from -H, -OH, $-NH_2$, $-NHR^{14}$, $-N(R^{14})_2$, $-C_1$-C_8 alkyl, $-C_3$-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, $-C_1$-C_8 alkyl-aryl, $-C_1$-C_8 alkyl-(C_3-C_8 carbocycle), C_3-C_8 heterocycle and $-C_1$-C_8 alkyl-(C_3-C_8 heterocycle);

Each R^{14} is independently -H or $-C_1$-C_8 alkyl; and

R^{15} is selected from -arylene-, $-C_3$-C_8 carbocyclo and $-C_3$-C_8 heterocyclo-; or

(b) a Drug unit of the formula:



wherein, independently at each location:

R^2 is selected from -H and $-C_1$-C_8 alkyl;

R^3 is selected from -H, $-C_1$-C_8 alkyl, $-C_3$-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, $-C_1$-C_8 alkyl-aryl, $-C_1$-C_8 alkyl-(C_3-C_8 carbocycle), $-C_3$-C_8 heterocycle and $-C_1$-C_8 alkyl-(C_3-C_8 heterocycle);

R^4 is selected from -H, $-C_1$-C_8 alkyl, $-C_3$-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, $-C_1$-C_8 alkyl-aryl, $-C_1$-C_8 alkyl-(C_3-C_8 carbocycle), $-C_3$-C_8 heterocycle and $-C_1$-C_8 alkyl-(C_3-C_8 heterocycle) wherein R^5 is selected from -H and -methyl; or R^4 and R^5 join, have the formula $-(CR^aR^b)_n-$ wherein R^a and R^b are independently selected from -H, $-C_1$-C_8 alkyl and $-C_3$-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

R^6 is selected from -H and $-C_1$-C_8 alkyl;

R^7 is selected from -H, $-C_1$-C_8 alkyl, $-C_3$-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, $-C_1$-C_8 alkyl-aryl, $-C_1$-C_8 alkyl-(C_3-C_8 carbocycle), $-C_3$-C_8 heterocycle and $-C_1$-C_8 alkyl-(C_3-C_8 heterocycle);

each R^8 is independently selected from -H, -OH, $-C_1$-C_8 alkyl, $-C_3$-C_8 carbocycle and -O-(C_1-C_8 alkoxy);

R^9 is selected from -H and $-C_1$-C_8 alkyl;

R^{10} is selected from



10. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -D is a Drug unit having the structure



11. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 3 where -D is a Drug unit having the structure



or a pharmaceutically acceptable salt or solvate thereof,

wherein, independently at each location:

R^1 is selected from -H and -methyl;

R^2 is selected from -H and -methyl;

R^3 is selected from -H, -methyl, and -isopropyl;

R^4 is selected from -H and -methyl; R^5 is selected from -isopropyl, -isobutyl, -sec-butyl, -methyl and -t-butyl or R^4 and R^5 join, have the formula $-(CR^aR^b)_n-$ where R^a and R^b are independently selected from -H, $-C_1-C_8$ alkyl, and $-C_3-C_8$ carbocycle, and N is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

R^6 is selected from -H and -methyl;

each R^8 is independently selected from -OH, -methoxy and -ethoxy;

when R^1 is -methyl, R^{10} is selected from



;

-;



;



;



; or



,

where X is -O-, -NH- or -N(R^{14})- and forms a bond with Y when y is 1 or 2, with W when y is 0, and with A when w and y are both 0;

Z is -O-, -NH- or -N(R^{14})-;

R^{13} is -H or -methyl;

R^{14} is C_1-C_8 alkyl; and

R^{15} is -arylene-, -C_3-C_8 carbocyclo or -C_3-C_8 heterocyclo-,

when R^1 is -H, R^{10} is selected from:



;



;



; or



,

where X is -O-, -NH- or -N(R^{14})- and forms a bond with Y when y is 1 or 2, with W when y is 0, and with A when w and y are both 0;

Z is -O-, -NH- or -N(R^{14})-;

R^{13} is -H or -methyl;

R^{14} is C_1-C_8 alkyl; and

R^{15} is -arylene-, -C_3-C_8 carbocyclo or -C_3-C_8 heterocyclo-.

12. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 3 where -D is a Drug unit having the structure



13. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 3 where -D is a Drug unit having the structure



14. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 3 where -D is a Drug unit having the structure



15. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 3 where -D is a Drug unit having the structure



16. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 3 where -D is a Drug unit having the structure



17. A compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3 or 5 where the Ligand unit is an antibody unit.

18. The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 17 where the antibody unit is a monoclonal antibody unit.

19. The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 18 where the monoclonal antibody unit is cBR96, cAC10 or 1F6.

20. The compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1 or 3 where -Y_y- is



Q is selected from -C_1-C_8 alkyl, -O-(C_1-C_8 alkyl), -halogen, -nitro and -cyano; and m is an integer ranging from 0-4, the amino terminus of -Y_y- forming a bond with a Amino acid unit and the carboxyl terminus of -Y_y- forming a bond with an Drug unit.

21. The compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3 or 5 where -A- is



and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the succinimido terminus of -Y_y- forming a bond with a Ligand unit.

22. The compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3 or 5 where -A- is



and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the amidomethyl terminus of -A- forming a bond with a Ligand unit.

23. The compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3 or 5 where -A- is



and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the succinimido terminus of -A- forming a bond with a Ligand unit.

24. The compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3 or 5 where -A- is



and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the succinimido terminus of -A- forming a bond with a Ligand unit.

25. The compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3 or 5 where -A- is



and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the amidomethyl terminus of -A- forming a bond with a Ligand unit.

26. The compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3 or 5 where -A- is



the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the amidomethyl terminus of -A- forming a bond with a Ligand unit.

27. The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 21 where -A- is



the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the succinimido terminus of -A- forming a bond with a Ligand unit.

28. The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 22 where -A- is



the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the amidomethyl terminus of -A- forming a bond with a Ligand unit.

29. The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 24 where -A- is



the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the succinimido terminus of -A- forming a bond with a Ligand unit.

30. The compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3 or 5 where $-W_w-$ is -Phenylalanine-Lysine-, the amino terminus of $-W_w-$ forming a bond with a Stretcher unit when a is 1 or with a Ligand unit if a is 0, and the C- terminus of $-W_w-$ forming a bond with a Spacer unit when y is 1 or 2, and with a Drug unit when y is 0.

31. The compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3 or 5 where $-W_w-$ is -valine-citrulline-, the amino terminus of $-W_w-$ forming a bond with a Stretcher unit when a is 1 or with a Ligand unit if a is 0, and the C- terminus of $-W_w-$ forming a bond with a Spacer unit when y is 1 or 2, and with a Drug unit when y is 0.

32. A compound of the formula



or a pharmaceutically acceptable salts or solvate thereof

wherein, independently at each location:

R^1 is selected from -H, $-C_1-C_8$ alkyl and $-C_3-C_8$ carbocycle; and R^2 is selected from -H and $-C_1-C_8$ alkyl; or R^1 and R^2 join, have the formula $-(CR^aR^b)_n-$ wherein R^a and R^b are independently selected from -H, $-C_1-C_8$ alkyl and $-C_3-C_8$ carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached;

R^3 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

R^4 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle) wherein R^5 is selected from -H and -methyl; or R^4 and R^5 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

R^6 is selected from -H and -C_1-C_8 alkyl;

R^7 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

each R^8 is independently selected from -H, -OH, -C_1-C_8 alkyl, -C_3-C_8 carbocycle and -O-(C_1-C_8 alkoxy);

R^9 is selected from -H and -C_1-C_8 alkyl;

X is -O-, -S-, -NH- or -$N(R^{14})$-;

each R^{12} is independently selected from -aryl and -C_3-C_8 heterocycle;

R^{13} is selected from -H, -OH,-NH_2, -NHR^{14}, -$N(R^{14})_2$, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

each R^{14} is independently -H or -C_1-C_8 alkyl;

R^{16} is -Yy-Ww-A'

wherein

each -W- is independently an Amino Acid unit;

-Y- is a Spacer unit;

w is an integer ranging from 0 to 12;

y is 0, 1 or 2; and

-A' is selected from

 ;

 ;

 ;

 ;

 ;

 ;

 ;

 ; and

 ;

wherein

G is selected from -Cl, -Br, -I, -O-mesyl and -O-tosyl;

J is selected from -Cl, -Br, -I, -F, -OH, -O-N-succinimide, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR^{18};

R^{17} is selected from -C_1-C_{10} alkylene-, -C_3-C_8 carbocyclo-, -O-(C_1-C_8 alkoxy)-, -arylene-, -C_1-C_{10} alkylene-arylene-, -arylene-C_1-C_{10} alkylene-, -C_1-C_{10} alkylene-(C_3-C_8 carbocyclo)-, -(C_3-C_8 carbocyclo)-C_1-C_{10} alkylene-, -C_3-C_8 heterocyclo-, -C_1-C_{10} alkylene-(C_3-C_8 heterocyclo)-, -(C_3-C_8 heterocyclo)-C_1-C_{10} alkylene-, -$(CH_2CH_2O)_r$-, and -$(CH_2CH_2O)_r$-CH_2-;

r is an integer ranging from 1-10; and

R^{18} is -C_1-C_8 alkyl or -aryl.

33. The compound of claim 32 having the structure



or a pharmaceutically acceptable salt or solvate thereof.

34. A compound of the formula



or a pharmaceutically acceptable salt or solvate thereof

wherein, independently at each location:

R^1 is selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle; and R^2 is selected from -H and -C_1-C_8 alkyl; or R^1 and R^2 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached;

R^3 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

R^4 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle) wherein R^5 is selected from -H and -methyl; or R^4 and R^5 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

R^6 is selected from -H and -C_1-C_8 alkyl;

R^7 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

each R^8 is independently selected from -H, -OH, -C_1-C_8 alkyl, -C_3-C_8 carbocycle and -O-(C_1-C_8 alkoxy);

R^9 is selected from -H and -C_1-C_8 alkyl;

X is -O-, -S-, -NH- or -N(R^{14})-;

R^{11} is selected from -H, -OH, -NH_2, -NHR^{14}, -N(R^{14})$_2$, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle); or R^{11} is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;

R^{13} is selected from -H, -OH, -NH_2, -NHR^{14}, -N(R^{14})$_2$, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

each R^{14} is independently -H or -C_1-C_8 alkyl;

R^{15} is selected from -arylene-, -C_3-C_8 carbocyclo- and -C_3-C_8 heterocyclo-;

R^{16} is -Yy-Ww-A'

wherein

each -W- is independently an Amino Acid unit;

-Y- is a Spacer unit;

w is an integer ranging from 0 to 12;

y is 0, 1 or 2; and

-A' is

 ;

 ;

 ;

 ;

 ;

 ;

 ;

 ; and

 ;

wherein

G is selected from -Cl, -Br, -I, -O-mesyl and -O-tosyl;

J is selected from -Cl, -Br, -I, -F, -OH, -O-N-succinimide, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR^{18};

R^{17} is selected from -C_1-C_{10} alkylene-, -C_3-C_8 carbocyclo-, -O-(C_1-C_8 alkoxy)-, -arylene-, -C_1-C_{10} alkylene-arylene-, -arylene-C_1-C_{10} alkylene-, -C_1-C_{10} alkylene-(C_3-C_8 carbocyclo)-, -(C_3-C_8 carbocyclo)-C_1-C_{10} alkylene-, -C_3-C_8 heterocyclo-, -C_1-C_{10} alkylene-(C_3-C_8 heterocyclo)-, -(C_3-C_8 heterocyclo)-C_1-C_{10} alkylene-, -$(CH_2CH_2O)_r$-, and -$(CH_2CH_2O)_r$-CH_2-;

r is an integer ranging from 1-10; and

R^{18} is -C_1-C_8 alkyl or -aryl.

35. A compound of the formula



or a pharmaceutically acceptable salt or solvate thereof

wherein, independently at each location:

R^1 is selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle; and R^2 is selected from -H and -C_1-C_8 alkyl; or R^1 and R^2 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached;

R^3 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

R^4 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle) wherein R^5 is selected from -H and -methyl; or R^4 and R^5 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

R^6 is selected from -H and -C_1-C_8 alkyl;

R^7 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

each R^8 is independently selected from -H, -OH, -C_1-C_8 alkyl, -C_3-C_8 carbocycle and -O-(C_1-C_8 alkoxy);

R^9 is selected from -H and -C_1-C_8 alkyl;

X is -O-, -S-, -NH- or -$N(R^{14})$-;

R^{11} is selected from -H, -OH, -NH_2, -NHR^{14}, -$N(R^{14})_2$, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle); or R^{11} is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;

each R^{12} is independently selected from -aryl and -C_3-C_8 heterocycle;

each R^{14} is independently -H or -C_1-C_8 alkyl;

R^{16} is -Yy-Ww-A'

wherein

each -W- is independently an Amino Acid unit;

-Y- is a Spacer unit;

w is an integer ranging from 0 to 12;

y is 0, 1 or 2; and

-A' is selected from


;


;


;


;


;


;


;


;

and


;

;

;

wherein

G is selected from -Cl, -Br, -I, -O-mesyl and -O-tosyl;

J is selected from -Cl, -Br, -I, -F, -OH, -O-N-succinimide, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR^{18};

R^{17} is selected from -C_1-C_{10} alkylene-, -C_3-C_8 carbocyclo-, -O-(-C_1-C_8 alkoxy)-, -arylene-, -C_1-C_{10} alkylene-arylene-, -arylene-C_1-C_{10} alkylene-, -C_1-C_{10} alkylene-(C_3-C_8 carbocyclo)-, -(C_3-C_8 carbocyclo)-C_1-C_{10} alkylene-, -C_3-C_8 heterocyclo-, -C_1-C_{10}

alkylene-(C_3-C_8 heterocyclo)-, -(C_3-C_8 heterocyclo)-C_1-C_{10} alkylene-, -$(CH_2CH_2O)_r$-, and -$(CH_2CH_2O)_r$-CH_2-;

r is an integer ranging from 1-10; and

R^{18} is -C_1-C_8 alkyl or -aryl.

36. A compound of the formula



or a pharmaceutically acceptable salt or solvate thereof

wherein, independently at each location:

R^1 is selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle; and R^2 is selected from -H and -C_1-C_8 alkyl; or R^1 and R^2 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached;

R^3 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

R^4 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle) wherein R^5 is selected from -H and -methyl; or R^4 and R^5 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

R^6 is selected from -H and -C_1-C_8 alkyl;

R^7 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

each R^8 is independently selected from -H, -OH, -C_1-C_8 alkyl, -C_3-C_8 carbocycle and -O-(C_1-C_8 alkoxy);

R^9 is selected from -H and -C_1-C_8 alkyl;

X is -O-, -S-, -NH- or -N(R^{14})-;

R^{11} is selected from -H, -OH, -NH_2, -NHR^{14}, -$N(R^{14})_2$, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle); or R^{11} is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;

each R^{12} is independently selected from -aryl and -C_3-C_8 heterocycle;

each R^{14} is independently -H or -C_1-C_8 alkyl;

R^{16} is -Yy-Ww-A'

wherein

each -W- is independently an Amino Acid unit;

-Y- is a Spacer unit;

w is an integer ranging from 0 to 12;

y is 0, 1 or 2; and

-A' is selected from


;


;


;


;


;


;


;


; and


;

wherein

G is selected from -Cl, -Br, -I, -O-mesyl and -O-tosyl;

J is selected from -Cl, -Br, -I, -F, -OH, -O-N-succinimide, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR^{18};

R^{17} is selected from -C_1-C_{10} alkylene-, -C_3-C_8 carbocyclo-, -O-(C_1-C_8 alkoxy)-, -arylene-, -C_1-C_{10} alkylene-arylene-, -arylene-C_1-C_{10} alkylene-, -C_1-C_{10} alkylene-(C_3-C_8 carbocyclo)-, -(C_3-C_8 carbocyclo)-C_1-C_{10} alkylene-, -C_3-C_8 heterocyclo-, -C_1-C_{10} alkylene-(C_3-C_8 heterocyclo)-, -(C_3-C_8 heterocyclo)-C_1-C_{10} alkylene-, -$(CH_2CH_2O)_r$-, and -$(CH_2CH_2O)_r$-CH_2-;

r is an integer ranging from 1-10; and

R^{18} is -C_1-C_8 alkyl or -aryl.

37. A compound of the formula



or a pharmaceutically acceptable salt or solvate thereof

wherein, independently at each location:

R^1 is selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle; and R^2 is selected from -H and -C_1-C_8 alkyl; or R^1 and R^2 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached;

R^3 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

R^4 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle) wherein R^5 is selected from -H and -methyl; or R^4 and R^5 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8

alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

R^6 is selected from -H and -C_1-C_8 alkyl;

R^7 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

each R^8 is independently selected from -H, -OH, -C_1-C_8 alkyl, -C_3-C_8 carbocycle and -O-(C_1-C_8 alkoxy);

R^9 is selected from -H and -C_1-C_8 alkyl;

Z is -O-, -S-, -NH- or -N(R^{14})-;

R^{11} is selected from -H, -OH, -NH_2, -NHR^{14}, -N(R^{14})$_2$, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle); or R^{11} is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;

each R^{12} is independently selected from -aryl and -C_3-C_8 heterocycle;

each R^{14} is independently -H or -C_1-C_8 alkyl;

R^{15} is selected from -arylene-, -C_3-C_8 carbocyclo- and -C_3-C_8 heterocyclo-;

R^{16} is -Yy-Ww-A'

wherein

each -W- is independently an Amino Acid unit;

-Y- is a Spacer unit;

w is an integer ranging from 0 to 12;

y is 0, 1 or 2; and

-A' is selected from


;


;


;


;


;


;


;

and


;

wherein

G is selected from -Cl, -Br, -I, -O-mesyl and -O-tosyl;

J is selected from -Cl, -Br, -I, -F, -OH, -O-N-succinimide, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR^{18};

R^{17} is selected from -C_1-C_{10} alkylene-, -C_3-C_8 carbocyclo-, -O-(C_1-C_8 alkoxy)-, -arylene-, -C_1-C_{10} alkylene-arylene-, -arylene-C_1-C_{10} alkylene-, -C_1-C_{10} alkylene-(C_3-C_8 carbocyclo)-, -(C_3-C_8 carbocyclo)-C_1-C_{10} alkylene-, -C_3-C_8 heterocyclo-, -C_1-C_{10} alkylene-(C_3-C_8 heterocyclo)-, -(C_3-C_8 heterocyclo)-C_1-C_{10} alkylene-, -$(CH_2CH_2O)_r$-, and -$(CH_2CH_2O)_r$-CH_2-;

r is an integer ranging from 1-10; and

R^{18} is -C_1-C_8 alkyl or -aryl.

38. A compound of the formula



or a pharmaceutically acceptable salt or solvate thereof

wherein, independently at each location:

R^1 is selected from -C_1-C_8 alkyl and -C_3-C_8 carbocycle; and R^2 is selected from -H and -C_1-C_8 alkyl; or R^1 and R^2 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the nitrogen atom to which they are attached;

R^3 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

R^4 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle) wherein R^5 is selected from -H and -methyl; or R^4 and R^5 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

R^6 is selected from -H and -C_1-C_8 alkyl;

R^7 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

each R^8 is independently selected from -H, -OH, -C_1-C_8 alkyl, -C_3-C_8 carbocycle and -O-(C_1-C_8 alkoxy);

R^9 is selected from -H and -C_1-C_8 alkyl;

X is -O-, -S-, -NH- or -$N(R^{14})$-;

Z is -O-, -S-, -NH- or -$N(R^{14})$-;

R^{11} is selected from -H, -OH, -NH_2, -NHR^{14}, -$N(R^{14})_2$, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle); or R^{11} is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;

each R^{12} is independently selected from -aryl and -C_3-C_8 heterocycle;

each R^{14} is independently -H or -C_1-C_8 alkyl;

R^{15} is selected from -arylene-, -C_3-C_8 carbocyclo- and -C_3-C_8 heterocyclo-;

R^{16} is -Yy-Ww-A'

wherein

each -W- is independently an Amino Acid unit;

-Y- is a Spacer unit;

w is an integer ranging from 0 to 12;

y is 0, 1 or 2; and

-A' is selected from


;


;


;


;


;


;


;

;


;


;

;

;

and

;

wherein

G is selected from -Cl, -Br, -I, -O-mesyl and -O-tosyl;

J is selected from -Cl, -Br, -I, -F, -OH, -O-N-succinimide, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR^{18};

R^{17} is selected from -C_1-C_{10} alkylene-, -C_3-C_8 carbocyclo-, -O-(C_1-C_8 alkoxy)-, -arylene-, -C_1-C_{10} alkylene-arylene-, -arylene-C_1-C_{10} alkylene-, -C_1-C_{10} alkylene-(C_3-C_8 carbocyclo)-, -(C_3-C_8 carbocyclo)-C_1-C_{10} alkylene-, -C_3-C_8 heterocyclo-, -C_1-C_{10} alkylene-(C_3-C_8 heterocyclo)-, -(C_3-C_8 heterocyclo)-C_1-C_{10} alkylene-, -$(CH_2CH_2O)_r$-, and -$(CH_2CH_2O)_r$-CH_2-;

r is an integer ranging from 1-10; and

R^{18} is -C_1-C_8 alkyl or -aryl.

39. The compound of claim 38 having the structure



or a pharmaceutically acceptable salt or solvate thereof.

40. The compound of claim 38 having the structure



or a pharmaceutically acceptable salt or solvate thereof.

41. The compound of claim 38 having the structure



or a pharmaceutically acceptable salt or solvate thereof.

42. The compound of claim 38 having the structure



or a pharmaceutically acceptable salt or solvate thereof.

43. A compound of the formula



or a pharmaceutically acceptable salt or solvate thereof

wherein, independently at each location:

R^2 is selected from -H and -C_1-C_8 alkyl;

R^3 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

R^4 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle) wherein R^5 is selected from -H and -methyl; or R^4 and R^5 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

R^6 is selected from -H and -C_1-C_8 alkyl;

R^7 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

each R^8 is independently selected from -H, -OH, -C_1-C_8 alkyl, -C_3-C_8 carbocycle and -O-(C_1-C_8 alkoxy);

R^9 is selected from -H and -C_1-C_8 alkyl;

Z is -O-, -S-, -NH- or -N(R^{14})-;

R^{11} is selected from -H, -OH, -NH_2, -NHR^{14}, -N(R^{14})$_2$, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle); or R^{11} is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;

each R^{12} is independently selected from -aryl and -C_3-C_8 heterocycle;

each R^{14} is independently -H or -C_1-C_8 alkyl;

R^{16} is -Yy-Ww-A'

wherein

each -W- is independently an Amino Acid unit;

-Y- is a Spacer unit;

w is an integer ranging from 0 to 12;

y is 0, 1 or 2; and

-A' is selected from

 ;

 ;

 ;

 ;

 ;

 ;

 ;

 ; and

 ;

wherein

G is selected from -Cl, -Br, -I, -O-mesyl and -O-tosyl;

J is selected from -Cl, -Br, -I, -F, -OH, -O-N-succinimide, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR^{18};

R^{17} is selected from -C_1-C_{10} alkylene-, -C_3-C_8 carbocyclo-, -O-(C_1-C_8 alkoxy)-, -arylene-, -C_1-C_{10} alkylene-arylene-, -arylene-C_1-C_{10} alkylene-, -C_1-C_{10} alkylene-(C_3-C_8 carbocyclo)-, -(C_3-C_8 carbocyclo)-C_1-C_{10} alkylene-, -C_3-C_8 heterocyclo-, -C_1-C_{10} alkylene-(C_3-C_8 heterocyclo)-, -(C_3-C_8 heterocyclo)-C_1-C_{10} alkylene-, -$(CH_2CH_2O)_r$-, and -$(CH_2CH_2O)_r$-CH_2-;

r is an integer ranging from 1-10; and

R^{18} is -C_1-C_8 alkyl or -aryl.

44. A compound of the formula



or a pharmaceutically acceptable salt or solvate thereof

wherein, independently at each location:

R^2 is selected from -H and -C_1-C_8 alkyl;

R^3 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

R^4 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle) wherein R^5 is selected from -H and -methyl; or R^4 and R^5 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

R^6 is selected from -H and -C_1-C_8 alkyl;

R^7 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

each R^8 is independently selected from -H, -OH, -C_1-C_8 alkyl, -C_3-C_8 carbocycle and -O-(C_1-C_8 alkoxy);

R^9 is selected from -H and -C_1-C_8 alkyl;

R^{11} is selected from -H, -OH, -NH_2, -NHR^{14}, -$N(R^{14})_2$, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle); or R^{11} is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;

each R^{12} is independently selected from -aryl and -C_3-C_8 heterocycle;

R^{13} is selected from -H, -OH, -NH_2, -NHR^{14}, -$N(R^{14})_2$, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

each R^{14} is independently -H or -C_1-C_8 alkyl;

R^{16} is -Yy-Ww-A'

wherein

each -W- is independently an Amino Acid unit;

-Y- is a Spacer unit;

w is an integer ranging from 0 to 12;

y is 0, 1 or 2; and

-A' is selected from


;


;


;


;


;


;


;


;

;

;

;

; and

;

wherein

G is selected from -Cl, -Br, -I, -O-mesyl and -O-tosyl;

J is selected from -Cl, -Br, -I, -F, -OH, -O-N-succinimide, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR^{18};

R^{17} is selected from -C_1-C_{10} alkylene-, -C_3-C_8 carbocyclo-, -O-(C_1-C_8 alkoxy)-, -arylene-, -C_1-C_{10} alkylene-arylene-, -arylene-C_1-C_{10} alkylene-, -C_1-C_{10} alkylene-(C_3-C_8 carbocyclo)-, -(C_3-C_8 carbocyclo)-C_1-C_{10} alkylene-, -C_3-C_8 heterocyclo-, -C_1-C_{10} alkylene-(C_3-C_8 heterocyclo)-, -(C_3-C_8 heterocyclo)-C_1-C_{10} alkylene-, -$(CH_2CH_2O)_r$-, and -$(CH_2CH_2O)_r$-CH_2-;

r is an integer ranging from 1-10; and

R^{18} is -C_1-C_8 alkyl or -aryl.

45. The compound of claim 44 having the structure



or a pharmaceutically acceptable salt or solvate thereof.

46. The compound of claim 44 having the structure



or a pharmaceutically acceptable salt or solvate thereof.

47. The compound of claim 44 having the structure



or a pharmaceutically acceptable salt or solvate thereof.

48. The compound of claim 44 having the structure



or a pharmaceutically acceptable salt or solvate thereof.

49. The compound of claim 44 having the structure



or a pharmaceutically acceptable salt or solvate thereof.

50. The compound of claim 44 having the structure



or a pharmaceutically acceptable salt or solvate thereof.

51. The compound of claim 44 having the structure



or a pharmaceutically acceptable salt or solvate thereof.

52. The compound of claim 44 having the structure



or a pharmaceutically acceptable salt or solvate thereof.

53. The compound of claim 3 having the structure



where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

54. The compound of claim 1 having the structure



where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

55. The compound of claim 3 having the structure



where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

56. The compound of claim 1 having the structure



where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

57. The compound of claim 1 having the structure



where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

58. The compound of claim 3 having the structure



where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

59. The compound of claim 1 having the structure



where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

60. The compound of claim 5 having the structure



where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

61. The compound of claim 3 having the structure



where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

62. The compound of claim 3 having the structure



where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

63. The compound of claim 1 having the structure



where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

64. The compound of claim 1 having the structure



where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

65. The compound of claim 1 having the structure



where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

66. The compound of any one of claims 53-65 where p ranges from about 7 to about 9.

67. The compound of any one of claims 53-65 where p ranges from about 3 to about 5.

68. The compound of any one of claims 53-65 where p ranges from 1 to about 3.

69. A composition comprising an effective amount of a compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 1, 3, 5, 32, 34, 35, 36, 37, 38, 43 or 44; and a pharmaceutically acceptable carrier or vehicle.

70. A method for killing or inhibiting the multiplication of a tumor cell or cancer cell comprising administering to an animal in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 1, 3, 5, 32, 34, 35, 36, 37, 38, 43 or 44.

71. A method for treating cancer, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3, 5, 32, 34, 35, 36, 37, 38, 43 or 44.

72. A method for treating an autoimmune disease, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3, 5, 32, 34, 35, 36, 37, 38, 43 or 44.

73. A method for treating an infectious disease, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 3, 5, 32, 34, 35, 36, 37, 38, 43 or 44.

74. The method of claim 71 further comprising administering to the animal an effective amount of an anticancer agent.

75. The method of claim 72 further comprising administering to the animal an effective amount of an immunosuppressant agent.

76. The method of claim 73 further comprising administering to the animal an effective amount of an anti-infectious agent.

77. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof,
where p ranges from about 7 to about 9.

78. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof,
where p ranges from about 7 to about 9.

79. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof,
where p ranges from about 7 to about 9.

80. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof,
where p ranges from about 7 to about 9.

81. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof,
where p ranges from about 7 to about 9.

82. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof,
where p ranges from about 7 to about 9.

83. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof,

where p ranges from about 7 to about 9.

84. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof,

where p ranges from about 3 to about 5.

85. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof,

where p ranges from 1 to about 3.

86. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof.

87. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof.

88. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof.

89. A compound having the structure



AMENDED CLAIMS
received by the International Bureau on16 June 2004 :
claims 1,5, 7 are amended, 93-119 are added, claims 2-4,6 and 8-92 are unchanged.

R^6 is selected from -H and -C_1-C_8 alkyl;

R^7 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

each R^8 is independently selected from -H, -OH, -C_1-C_8 alkyl, -C_3-C_8 carbocycle and -O-(C_1-C_8 alkyl);

R^9 is selected from -H and -C_1-C_8 alkyl;

R^{10} is selected from



and

;

Z is -O-, -S-, -NH- or -N(R^{14})-;

R^{11} is selected from -H, -OH, -NH_2, -NHR^{14}, -N(R^{14})$_2$, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle); or R^{11} is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;

each R^{12} is independently selected from -aryl and -C_3-C_8 heterocycle;

R^{13} is selected from -H, -OH, -NH_2, -NHR^{14}, -N(R^{14})$_2$, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), C_3-C_8 heterocycle and -C_1-$_8$ alkyl-(C_3-C_8 heterocycle); and

Each R^{14} is independently -H or -C_1-C_8 alkyl.

2. The compound of claim 1 wherein w is an integer ranging from 2 to 12.

3. A compound of the formula Ib:



Ib

or a pharmaceutically acceptable salt or solvate thereof

ART 34 AMDT



Z is -O-, -S-, -NH- or -N(R^{14})-;

R^{11} is selected from -H, -OH, -NH_2, -NHR^{14}, -N(R^{14})$_2$, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle); or R^{11} is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;

each R^{12} is independently selected from -aryl and -C_3-C_8 heterocycle;

R^{13} is selected from -H, -OH, -NH_2, -NHR^{14}, -N(R^{14})$_2$, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle); and

each R^{14} is independently -H or -C_1-C_8 alkyl.

6. The compound of claim 5 wherein w is an integer ranging from 2 to 12.

7. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -D is a Drug unit having the structure



or a pharmaceutically acceptable salt or solvate thereof,

wherein, independently at each location:

R^2 is selected from -H and -methyl;

R^3 is selected from -H, -methyl, and -isopropyl;

R^4 is selected from -H and -methyl; R^5 is selected from -isopropyl, -isobutyl, -sec-butyl, -methyl and -t-butyl or R^4 and R^5 join, have the formula – (CR^aR^b)$_n$- where R^a and R^b are independently selected from -H, -C_1-C_8 alkyl, and -C_3-C_8 carbocycle, and n is

selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

R^6 is selected from -H and -methyl;

each R^8 is independently selected from -OH, -methoxy and -ethoxy;

R^{10} is selected from



R^{24} is selected from H and $-C(O)R^{25}-$; wherein R^{25} is selected from $-C_1-C_8$ alkyl, $-C_3-C_8$ carbocycle, -aryl, $-C_1-C_8$ alkyl-aryl, $-C_1-C_8$ alkyl-(C_3-C_8 carbocycle), $-C_3-C_8$ heterocycle and $-C_1-C_8$ alkyl-(C_3-C_8 heterocycle);

Z is -O-, -NH-, -OC(O)-, -NHC(O)-, $-NR^{28}C(O)-$; where R^{28} is selected from -H and $-C_1-C_8$ alkyl;

n is 0 or 1; and

R^{27} is selected from -H, $-N_3$, $-C_1-C_8$ alkyl, $-C_3-C_8$ carbocycle, -aryl, $-C_1-C_8$ alkyl-aryl, $-C_1-C_8$ alkyl-(C_3-C_8 carbocycle), $-C_3-C_8$ heterocycle and $-C_1-C_8$ alkyl-(C_3-C_8 heterocycle) when n is 0; and R^{27} is selected from -H, $-C_1-C_8$ alkyl, $-C_3-C_8$ carbocycle, -aryl, $-C_1-C_8$ alkyl-aryl, $-C_1-C_8$ alkyl-(C_3-C_8 carbocycle), $-C_3-C_8$ heterocycle and $-C_1-C_8$ alkyl-(C_3-C_8 heterocycle) when n is 1.

8. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -D is a Drug unit having the structure



9. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -D is a Drug unit having the structure

or a pharmaceutically acceptable salt or solvate thereof.

90. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof.

91. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof.

92. The compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 1, 3, 5, 32, 34, 35, 36, 37, 38, 43 or 44, in an isolated or a purified form.

93. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 7 to about 9.

94. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof, where p ranges from about 7 to about 9

95. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof,

where p ranges from about 7 to about 9; and L is an anti-CD20 antibody.

96. The compound of claim 95 wherein L is rituximab.

97. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof,

where p ranges from about 7 to about 9; and L is an anti-CD40 antibody.

98. The compound of claim 97 wherein L is S2C6.

99. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof,

where p ranges from about 7 to about 9; and L is an anti-CD20 antibody.

100. The compound of claim 99 wherein L is rituximab.

101. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof,

where p ranges from about 7 to about 9; and L is an anti-CD40 antibody.

102. The compound of claim 101 wherein L is S2C6.

103. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof,

where p ranges from about 7 to about 9; and L is an anti-CD20 antibody.

104. The compound of claim 103 wherein L is rituximab.

105. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof,

where p ranges from about 7 to about 9; and L is an anti-CD40 antibody.

106. The compound of claim 105 wherein L is S2C6.

107. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof,

where p ranges from about 7 to about 9; and L is an anti-CD20 antibody.

108. The compound of claim 107 wherein L is rituximab.

109. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof,

where p ranges from about 7 to about 9; and L is an anti-CD40 antibody.

110. The compound of claim 109 wherein L is S2C6.

111. A composition comprising an effective amount of a compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 77-91, 93-95, 97, 99, 101, 103, 105, 107 and 109 and a pharmaceutically acceptable carrier or vehicle.

112. A method for killing or inhibiting the multiplication of a tumor cell or cancer cell comprising administering to an animal in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 77-91, 93-95, 97, 99, 101, 103, 105, 107 and 109.

113. A method for treating cancer, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 77-91, 93-95, 97, 99, 101, 103, 105, 107 and 109.

114. A method for treating an autoimmune disease, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 77-91, 93-95, 97, 99, 101, 103, 105, 107 and 109.

115. A method for treating an infectious disease, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 77-91, 93-95, 97, 99, 101, 103, 105, 107 and 109.

116. The method of claim 113 further comprising administering to the animal an effective amount of an anticancer agent.

117. The method of claim 114 further comprising administering to the animal an effective amount of an immunosuppressant agent.

118. The method of claim 115 further comprising administering to the animal an effective amount of an anti-infectious agent.

119. The compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 77-91, 93-95, 97, 99, 101, 103, 105, 107 and 109, in an isolated or a purified form.